Skip to main content

Table 2 Clinical characteristics of major depressive patients (n = 78) at baseline and healthy controls (n = 10)

From: Alteration of transthyretin and thyroxine-binding globulin in major depressive disorder: multiple reaction monitoring-based proteomic analysis

Characteristics Control SSRIs Mirtazapine P
R NR R NR
N 10 19 16 22 21  
Age, mean ± SD, year 67.4 ± 6.7 65.9 ± 12.3 62.4 ± 10.2 66.4 ± 8.8 66.8 ± 9.4 0.884
Gender, M:F, n 3:7 6:13 4:12 6:16 6:15 0.996
HAM-D score, mean ± SD   19.0 ± 3.11 20.6 ± 2.76 18.2 ± 2.64 20.2 ± 3.79 0.320
Onset age, mean ± SD, year   56.4 ± 14.2 57.6 ± 9.66 56.5 ± 15.6 55.1 ± 14.5 0.573
No. of episode, mean ± SD   2.58 ± 1.92 1.75 ± 0.86 2.64 ± 2.06 3.33 ± 2.83 0.376
Duration of current episode, mean ± SD, m   4.21 ± 3.60 9.56 ± 7.89 3.86 ± 3.12 7.19 ± 6.59 0.105
Antidepressant used, n (%)       0.956
 Escitalopram   2 (10.5) 1 (6.3)    
 Fluoxetine   8 (42.1) 9 (56.3)    
 Paroxetine   5 (26.3) 3 (18.8)    
 Sertraline   4 (21.1) 3 (18.8)    
 Mirtazapine     22 21  
  1. HAM-D Hamilton Depression Rating Scale, NR nonresponders; R responder; SD standard deviation, SSRIs selective serotonin reuptake inhibitors